Erythropoiesis-stimulating agents in kidney and cardiac disease

被引：1
|
作者：
Fluck, Richard [1 ]
机构：
[1] Derby City Gen Hosp, Dept Renal Med, Derby DE22 3NE, England
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2006年 / 67卷 / 10期
关键词：
D O I：
10.12968/hmed.2006.67.10.22060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
for the last 20 years, erythropoiesis-stimulating agents have transformed the lives of renal dialysis patients, and they are now being used to correct anaemia in chronic kidney disease and after renal transplantation. In future, these drugs may be used outside the renal clinic to improve outcomes in patients with chronic heart failure.
引用
收藏
页码：533 / 537
页数：5
相关论文
共 50 条
  • [21] Emerging erythropoiesis-stimulating agents
    Robert N. Foley
    Nature Reviews Nephrology, 2010, 6 : 218 - 223
  • [22] Intersecting Guidelines: Administering Erythropoiesis-Stimulating Agents to Chronic Kidney Disease Patients with Cancer
    Bennett, Charles L.
    Becker, Pamela S.
    Kraut, Eric H.
    Samaras, Athena T.
    West, Dennis P.
    SEMINARS IN DIALYSIS, 2009, 22 (01) : 1 - 4
  • [23] Effect of erythropoiesis-stimulating agents on Healthcare utilization, costs, and outcomes in chronic kidney disease
    Maddux, Franklin W.
    Shetty, Sharashchandra
    Del Aguila, Michael A.
    Nelson, Michael A.
    Murray, Brian M.
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (11) : 1761 - 1769
  • [24] The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
    Roberto Robles, Nicolas
    CLINICAL DRUG INVESTIGATION, 2016, 36 (06) : 421 - 431
  • [25] Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient
    Schmid, Holger
    Schiffl, Helmut
    Lederer, Stephan R.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2011, 20 (05): : 465 - 470
  • [26] Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease
    Seliger, Stephen L.
    Zhang, Amy D.
    Weir, Matthew R.
    Walker, Loreen
    Hsu, Van Doren
    Parsa, Afshin
    Diamantidis, Clarissa J.
    Fink, Jeffrey C.
    KIDNEY INTERNATIONAL, 2011, 80 (03) : 288 - 294
  • [27] The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
    Nicolas Roberto Robles
    Clinical Drug Investigation, 2016, 36 : 421 - 431
  • [28] Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
    Kim, Sun Moon
    Kim, Kyeong Min
    Kwon, Soon Kil
    Kim, Hye-Young
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2016, 31 (01) : 55 - 60
  • [29] Equipotent Doses of Erythropoiesis-Stimulating Agents in Outpatients with Anaemia Secondary to Chronic Kidney Disease
    Escudero-Vilaplana, Vicente
    Martinez-Nieto, Concepcion
    Manuel Lopez-Gomez, Juan
    Vega-Martinez, Almudena
    Sanjurjo-Saez, Maria
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (03): : 454 - 458
  • [30] Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
    Aapro, Matti
    Gascon, Pere
    Patel, Kashyap
    Rodgers, George M.
    Fung, Selwyn
    Arantes, Luiz H., Jr.
    Wish, Jay
    FRONTIERS IN PHARMACOLOGY, 2019, 9
12345